Shantaram

[Shantaram @shenash2]

https://t.co/Gg3pUovCY4
FDA June 2026 OPOE List: 699 Immediate ANDA Opportunities, Lupin’s Kalydeco Patent Win, & Global GMP Warnings
#PharmaIP #FDA #GenericDrugs #HatchWaxman #Lupin #Kalydeco #PatentLaw #PharmaManufacturing #RegulatoryIntelligence #SidvimBlog

[Shantaram @shenash2]

Sidvim LifeSciences Private Limited: Pharma Intelligence Alert: 2021 USFDA 505(b)(2) Ap... https://t.co/smL4QHznNZ

[Shantaram @shenash2]

https://t.co/BGOAH5EoJY
USFDA July 2026 ANDA Approvals: Indian Pharma Dominance, Antidiabetic Waves, US Tariffs, & EPO Patent Insights
#PharmaNews #USFDA #ANDAFiling #GenericDrugs #PharmaIP #IndianPharma #PatentLitigation #SupplyChain #SidvimBlog

[Shantaram @shenash2]

https://t.co/BGOAH5EoJY
USFDA July 2026 ANDA Approvals: Indian Pharma Dominance, Antidiabetic Waves, US Tariffs, & EPO Patent Insights
#PharmaNews #USFDA #ANDAFiling #GenericDrugs #PharmaIP #IndianPharma #PatentLitigation #SupplyChain #SidvimBlog

[Shantaram @shenash2]

Sidvim LifeSciences Private Limited: Pharma Intelligence Alert: 2021 USFDA 505(b)(2) Ap... https://t.co/smL4QHznNZ

[Shantaram @shenash2]

https://t.co/TXHtfMdTNW
Pharma IP Alert: Tirzepatide P-IV Storm Hits FDA, US Generic Tariffs Loom, & Pfizer Tafamidis Discovery Ruling
#Pharma #Tirzepatide #Mounjaro #Zepbound #FDA #ANDAFiling #505b2 #PharmaNews #IntellectualProperty

[Shantaram @shenash2]

https://t.co/TXHtfMdTNW
Pharma IP Alert: Tirzepatide P-IV Storm Hits FDA, US Generic Tariffs Loom, & Pfizer Tafamidis Discovery Ruling
#Pharma #Tirzepatide #Mounjaro #Zepbound #FDA #ANDAFiling #505b2 #PharmaNews #IntellectualProperty

[Shantaram @shenash2]

https://t.co/lGHbAQyHdD
Pharma Market Briefing: Q2 2026 USFDA Type II DMF Filings, 505(b)(2) Strategy & EPO Update
#USFDADMF, #PharmaRegulations, #GenericDrugs, #IntellectualProperty, #SidvimPharmaUpdate

[Shantaram @shenash2]

https://t.co/lGHbAQyHdD
Pharma Market Briefing: Q2 2026 USFDA Type II DMF Filings, 505(b)(2) Strategy & EPO Update
#USFDADMF, #PharmaRegulations, #GenericDrugs, #IntellectualProperty, #SidvimPharmaUpdate

[Shantaram @shenash2]

Sidvim LifeSciences Private Limited: Pharma & Veterinary Briefing 2026: FDA Green Book ... https://t.co/srfmMezaWv

[Shantaram @shenash2]

Sidvim LifeSciences Private Limited: Pharma & Veterinary Briefing 2026: FDA Green Book ... https://t.co/srfmMezaWv

[Shantaram @shenash2]

https://t.co/t2CNePNfOX
Pharma & Veterinary Briefing 2026: FDA Green Book Exclusivities, Advanced Manufacturing, and Key IP Decisions
#PharmaRegulations #FDAUpdate #IntellectualProperty #PharmaPatents #GenericDrugs #GreenBook2026 #VeterinaryPharma #ANDALitigation

[Shantaram @shenash2]

https://t.co/t2CNePNfOX
Pharma & Veterinary Briefing 2026: FDA Green Book Exclusivities, Advanced Manufacturing, and Key IP Decisions
#PharmaRegulations #FDAUpdate #IntellectualProperty #PharmaPatents #GenericDrugs #GreenBook2026 #VeterinaryPharma #ANDALitigation

[Shantaram @shenash2]

https://t.co/ScOllT5nzb
1.) June ANDA Approvals, Formulation Tech and 2.) CAFC Patent Decisions: Why the Federal Circuit Invalidated Enanta’s Protease Inhibitor Patent Against Pfizer
#PharmaRegulations, #ANDAWactch, #IntellectualProperty, #PharmaPatents, #GenericDrugs, #FDAApproval, #BiotechIP, #FormulationTech

[Shantaram @shenash2]

https://t.co/ScOllT5nzb
1.) June ANDA Approvals, Formulation Tech and 2.) CAFC Patent Decisions: Why the Federal Circuit Invalidated Enanta’s Protease Inhibitor Patent Against Pfizer
#PharmaRegulations, #ANDAWactch, #IntellectualProperty, #PharmaPatents, #GenericDrugs, #FDAApproval, #BiotechIP, #FormulationTech

[Shantaram @shenash2]

https://t.co/6QM2xKNksx
1.) How Casper and Avyxa Are Using the 505(b)(2) Pathway to Drive Patient-Centric Formulation Innovation? 2.) Why the EPO Revoked Astellas’ Mirabegron Patent?
#PharmaRegulations, #505b2, #IntellectualProperty, #PharmaPatent, #GenericDrugs, #FDAApproval, #OncologyCare, #RareDisease, #EPOLaw

[Shantaram @shenash2]

https://t.co/6QM2xKNksx
1.) How Casper and Avyxa Are Using the 505(b)(2) Pathway to Drive Patient-Centric Formulation Innovation? 2.) Why the EPO Revoked Astellas’ Mirabegron Patent?
#PharmaRegulations, #505b2, #IntellectualProperty, #PharmaPatent, #GenericDrugs, #FDAApproval, #OncologyCare, #RareDisease, #EPOLaw

[Shantaram @shenash2]

https://t.co/eDmwp2h8xs
Paragraph IV Updates 2026: Camzyos Patent Challenges & REBYOTA IP Ruling

#PharmaNews #IntellectualProperty #USFDA #ParagraphIV #Camzyos #REBYOTA #Biopharma2026

[Shantaram @shenash2]

https://t.co/G14kkp4z2w
Pharma Regulatory & IP Digest: 2026 CGT Trends, GLP-1 Breakthroughs, and EPO Patent Rulings

[Shantaram @shenash2]

https://t.co/eDmwp2h8xs
Paragraph IV Updates 2026: Camzyos Patent Challenges & REBYOTA IP Ruling

#PharmaNews #IntellectualProperty #USFDA #ParagraphIV #Camzyos #REBYOTA #Biopharma2026